Cargando…

Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice

BACKGROUND: RA patients being treated with biologics are known to have an increased risk of infections. We recently demonstrated that both CTLA4 Ig and anti-TNF treatment aggravate systemic Staphylococcus aureus (S. aureus) infection in mice, but with distinct clinical manifestations. However, the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Na, Manli, Wang, Wanzhong, Fei, Ying, Josefsson, Elisabet, Ali, Abukar, Jin, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338833/
https://www.ncbi.nlm.nih.gov/pubmed/28264025
http://dx.doi.org/10.1371/journal.pone.0173492
_version_ 1782512564454817792
author Na, Manli
Wang, Wanzhong
Fei, Ying
Josefsson, Elisabet
Ali, Abukar
Jin, Tao
author_facet Na, Manli
Wang, Wanzhong
Fei, Ying
Josefsson, Elisabet
Ali, Abukar
Jin, Tao
author_sort Na, Manli
collection PubMed
description BACKGROUND: RA patients being treated with biologics are known to have an increased risk of infections. We recently demonstrated that both CTLA4 Ig and anti-TNF treatment aggravate systemic Staphylococcus aureus (S. aureus) infection in mice, but with distinct clinical manifestations. However, the effects of CTLA4 Ig and anti-TNF treatments on a local S. aureus infection (e.g., skin infection) might differ from their effects on a systemic infection. AIMS: The aim of this study was to examine the differential effects of anti-TNF versus CTLA4 Ig treatment on S. aureus skin infections in mice. METHOD: Abatacept (CTLA4 Ig), etanercept (anti-TNF treatment) or PBS was given to NMRI mice subcutaneously inoculated with S. aureus strain SH1000. The clinical signs of dermatitis, along with histopathological changes due to skin infection, were compared between the groups. RESULTS: Both CTLA4 Ig and anti-TNF treatment resulted in less severe skin infections and smaller post-infectious hyperpigmentation compared with controls. Consistent with the clinical signs of dermatitis, smaller lesion size, more epithelial hyperplasia and more granulation were found in skin biopsies from mice receiving anti-TNF compared with PBS controls. However, both CTLA4 Ig and anti-TNF therapy tended to prolong the healing time, although this finding was not statistically significant. Serum MCP-1 levels were elevated in the anti-TNF group relative to the CTLA4 Ig and PBS groups, whereas IL-6 levels were higher in PBS controls than in the other two groups. Both anti-TNF and CTLA4 Ig treatments tended to down-regulate the necrosis/apoptosis ratio in the locally infected skin tissue. Importantly, no tangible difference was found in the bacterial burden among groups. CONCLUSION: Both CTLA4 Ig and anti-TNF therapies attenuate disease severity but may prolong the healing time required for S. aureus skin infections. Neither treatment has an impact on bacterial clearance in skin tissues.
format Online
Article
Text
id pubmed-5338833
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-53388332017-03-10 Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice Na, Manli Wang, Wanzhong Fei, Ying Josefsson, Elisabet Ali, Abukar Jin, Tao PLoS One Research Article BACKGROUND: RA patients being treated with biologics are known to have an increased risk of infections. We recently demonstrated that both CTLA4 Ig and anti-TNF treatment aggravate systemic Staphylococcus aureus (S. aureus) infection in mice, but with distinct clinical manifestations. However, the effects of CTLA4 Ig and anti-TNF treatments on a local S. aureus infection (e.g., skin infection) might differ from their effects on a systemic infection. AIMS: The aim of this study was to examine the differential effects of anti-TNF versus CTLA4 Ig treatment on S. aureus skin infections in mice. METHOD: Abatacept (CTLA4 Ig), etanercept (anti-TNF treatment) or PBS was given to NMRI mice subcutaneously inoculated with S. aureus strain SH1000. The clinical signs of dermatitis, along with histopathological changes due to skin infection, were compared between the groups. RESULTS: Both CTLA4 Ig and anti-TNF treatment resulted in less severe skin infections and smaller post-infectious hyperpigmentation compared with controls. Consistent with the clinical signs of dermatitis, smaller lesion size, more epithelial hyperplasia and more granulation were found in skin biopsies from mice receiving anti-TNF compared with PBS controls. However, both CTLA4 Ig and anti-TNF therapy tended to prolong the healing time, although this finding was not statistically significant. Serum MCP-1 levels were elevated in the anti-TNF group relative to the CTLA4 Ig and PBS groups, whereas IL-6 levels were higher in PBS controls than in the other two groups. Both anti-TNF and CTLA4 Ig treatments tended to down-regulate the necrosis/apoptosis ratio in the locally infected skin tissue. Importantly, no tangible difference was found in the bacterial burden among groups. CONCLUSION: Both CTLA4 Ig and anti-TNF therapies attenuate disease severity but may prolong the healing time required for S. aureus skin infections. Neither treatment has an impact on bacterial clearance in skin tissues. Public Library of Science 2017-03-06 /pmc/articles/PMC5338833/ /pubmed/28264025 http://dx.doi.org/10.1371/journal.pone.0173492 Text en © 2017 Na et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Na, Manli
Wang, Wanzhong
Fei, Ying
Josefsson, Elisabet
Ali, Abukar
Jin, Tao
Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice
title Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice
title_full Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice
title_fullStr Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice
title_full_unstemmed Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice
title_short Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice
title_sort both anti-tnf and ctla4 ig treatments attenuate the disease severity of staphylococcal dermatitis in mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338833/
https://www.ncbi.nlm.nih.gov/pubmed/28264025
http://dx.doi.org/10.1371/journal.pone.0173492
work_keys_str_mv AT namanli bothantitnfandctla4igtreatmentsattenuatethediseaseseverityofstaphylococcaldermatitisinmice
AT wangwanzhong bothantitnfandctla4igtreatmentsattenuatethediseaseseverityofstaphylococcaldermatitisinmice
AT feiying bothantitnfandctla4igtreatmentsattenuatethediseaseseverityofstaphylococcaldermatitisinmice
AT josefssonelisabet bothantitnfandctla4igtreatmentsattenuatethediseaseseverityofstaphylococcaldermatitisinmice
AT aliabukar bothantitnfandctla4igtreatmentsattenuatethediseaseseverityofstaphylococcaldermatitisinmice
AT jintao bothantitnfandctla4igtreatmentsattenuatethediseaseseverityofstaphylococcaldermatitisinmice